CJC-1295 (no DAC)
Mod GRF 1-29 · Modified GRF (1-29)
A stabilised GHRH fragment that amplifies each natural GH pulse — the standard partner to a secretagogue.
Class
Growth-hormone-releasing hormone (GHRH) analogue
Half-life
~30 minutes
Evidence
Animal models
Animal models
Evidence comes primarily from rodent or other animal studies. Translation to humans is unproven.
Overview
CJC-1295 without DAC — more accurately Modified GRF (1-29) — is a shortened, stabilised analogue of growth-hormone-releasing hormone. Four amino-acid substitutions protect it from enzymatic breakdown, extending a native GHRH half-life of minutes to roughly half an hour.
GHRH increases the amplitude of GH pulses. A ghrelin-mimetic like ipamorelin increases their frequency and works through a separate receptor. Combined, the two produce a larger, more physiological GH release than either alone — which is why the 'CJC + ipamorelin' pairing is the most common secretagogue stack.
The 'no DAC' distinction matters. The DAC (drug affinity complex) version binds albumin and lasts about a week, producing sustained elevated GH — a 'bleed' rather than a pulse — which many consider less physiological. The no-DAC version preserves pulsatility. Neither is approved for human use.
How it works
- Binds pituitary GHRH receptors, increasing the amplitude of endogenous GH pulses.
- Amino-acid substitutions at positions 2, 8, 15, and 27 resist DPP-4 degradation.
- Short half-life produces a discrete pulse rather than sustained elevation, preserving feedback.
- Synergises with GHS-R agonists (ipamorelin, GHRP-2/6) that act via the parallel ghrelin pathway.
What the research shows
Researched effects
- Amplified GH pulse amplitude and downstream IGF-1 in pharmacology studies
- Synergistic GH release when combined with a secretagogue
- Anecdotal improvement in recovery, sleep, and body composition
- Preserves natural pulsatility unlike the DAC version
Limitations & what it won't do
- No controlled human efficacy trials for body composition outcomes.
- Must be timed away from food — carbohydrate and fat blunt the GH response.
- Effect is modest and additive to good training and sleep, not a substitute.
- Not FDA approved.
Dosing protocols
These ranges reflect published trials and community protocols. They are reference information, not a prescription. Doses are per injection unless noted.
Standard GHRH protocol
100 mcgAlmost always paired 1:1 with ipamorelin. 100 mcg approximates the saturation dose per injection.
Reconstitution & measuring your dose
Handling
- Typical vial sizes
- 2 · 5 mg
- Suggested BAC water
- 2 mL
- Storage
- Lyophilised powder refrigerated at 2–8 °C, protected from light.
- After reconstitution
- Reconstituted: approximately 30 days refrigerated. Do not freeze.
Why 2 mL? A 5 mg vial in 2 mL yields 2500 mcg/mL — 100 mcg lands on 4 units of a U-100 syringe. Pairs cleanly with an ipamorelin vial reconstituted the same way.
Dose calculator
Draw to
4units
= 0.04 mL · 25 mcg per unit
Concentration
2500 mcg/mL
Doses per vial
50
Side effects
Common
- Facial flushing shortly after injection
- Head rush / lightheadedness
- Water retention
- Injection-site reactions
- Tingling in extremities
Serious / rare
- Reduced insulin sensitivity with prolonged use
- Theoretical tumour stimulation via IGF-1
Contraindications & interactions
Do not use if you have
- Active cancer or current oncology treatment
Raises IGF-1; contraindicated during active malignancy.
- Pregnant, breastfeeding, or trying to conceive
No pregnancy safety data.
Use caution if you have
- Type 2 diabetes or insulin resistance
GH pulses reduce insulin sensitivity — monitor glucose.
- Type 1 diabetes
Requires insulin coordination.
- Past cancer diagnosis (in remission)
IGF-1 elevation warrants oncology clearance.
- Carpal tunnel or nerve compression
Fluid retention can aggravate nerve compression.
Medication interactions
- monitorInsulin — GH opposes insulin; glucose may rise.
- cautionGrowth hormone (rhGH) — Redundant with exogenous rhGH.
- monitorCorticosteroids — Steroids blunt the GH response.
What to monitor
- Fasting glucose and HbA1c
- IGF-1 if available
- Fluid status and blood pressure
Commonly combined with
References
- Teichman SL et al. — Prolonged stimulation of GH and IGF-I by CJC-1295J Clin Endocrinol Metab 2006;91:799-805
Research & educational information only — not medical advice.
You must be 18 or older to use this site. The peptides described are presented as research chemicals intended for research purposes only. Most are not approved by the FDA for human use. Dosing ranges reflect what has appeared in the scientific literature or community protocols and are not prescriptions. Nothing here replaces evaluation by a licensed physician who knows your full medical history.
Want to know if CJC-1295 (no DAC) fits your goals and history?
The assessment cross-checks your medical history and medications against this and every other compound before it recommends anything.
Start the assessment